INTRODUCTION
The extraordinary polymorphism of the HL-A leukocyte antigen system strongly implies that natural selection has played a role in its generation. The association of the mouse analogue, H-2, with disease susceptibility, especially leukemia (1, 2) , offers one example of how selection may operate. Thus, searches for disease-HL-A antigen associations in man are warranted, although the associations may not be as clear-cut as in the inbred mouse strains. In addition to providing reasons for the polymorphism, the association of particular HL-A antigens with disease may yield some clues to the pathogenesis of these conditions. Moreover, these associations identify individuals at risk and thus may facilitate earlier diagnosis.
Disease-antigen searches should consider first those diseases which are prevalent before or during the reproductive years and, thus, exert a natural selective pressure on the gene pool. Acute lymphocytic leukemia (ALL) 1 is a disease affecting members of the species at this time and is a logical choice for study.
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Several investigators have already studied this disease and conflicting results have been published (3) (4) (5) (6) (7) (8) . The present study differs from the previous investigations in that it presents a larger number of patients and their families who have been completely genotyped.
HL-A antigens of 50 Caucasian patients with ALL and their families were assessed. We found a significant increase in HL-A2 in these patients.
METHODS
The lymphocyte cytotoxicity technique of Mittal, Mickey, Singal, and Terasaki (9) with slight modification in the preparation of lymphocyte suspensions was used to assess HL-A antigens. Heparinized blood was poured over nylon columns (1 g for 10-15 ml of blood) and the effluent was sedimented with Plasmagel at 370C. Lymphocytes were removed by centrifugation of the upper layer of the sedimented blood and contaminating erythrocytes were then agglutinated by chicken anti-human erythrocyte sera (10) . The remainder of the preparation of lymphocytes and the cytotoxicity test itself are as described by Mittal et al. (9) . Sera used to detect HL-A antigens were obtained from the Serum Bank maintained by the Transplantation and Immunology Branch of the National Institute of Allergy and Infectious Diseases. Other sera were kindly provided by Doctors M. Jeannet and F. Kissmeyer-Nielsen. Some sera were purchased from Hyland Laboratories, Los Angeles, Calif. Antigens typed for included HL-A1, 2, 3, 5, 7, 8, 9, 10, 11, 12, Lc17 (W28 or Ba*), Thompson (Th, W19), W14, W10, and Te5O. In all instances except Lc17, Thompson , and W-14, at least 2 and often as many as 10 sera were used to define each specificity. Sera used to detect HL-A2 included Pinquette (NIH code No. 50-6-03-08-01 and 50-6-03-01-04), Piquard (01-8-03-06-04 and 01-9-07-17-02), Revillard (01-7-02-07-02), Ter. 8 (53-6-01-17-01), Wroten (57-9-03-14-10), D66-17077 IV (03-7-03-21-12), Hyland A2 (code 0966H003A1), and our own serum Stengel. We find that the first listed Piquard serum also detects Lc17; Revillard, Stengel, and Wroten are occasionally positive with non-HL-A2 cells.
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An antigen was assigned to a cell when greater than 80% of all sera reacted with the cell. The reproducibility of the procedure was 97%o when tested on normal individuals. There was more variability when testing disease subjects, however repeat typings were carried out on many of the patients, and assignment of antigens could be made with a high degree of confidence.
50 Caucasian children and their families (in most instances complete families) were HL-A typed. Genotyping was done on all members of the family. In the few ambiguous situations (e.g., family 50) crossing-over was assumed not to occur. As controls, 200 unrelated normal Caucasian blood bank donors were HL-A phenotyped with the same sera.
Gene frequencies for the various HL-A antigens were assessed by direct counting in the ALL population and by the method of iterative maximum likelihood estimation assuming the Hardy-Weinberg Law (11, pp. 165-172) in the normal population. In each of the two segregational series, the over-all test of possible difference in gene frequencies between the two groups was done by Fisher's discrepancy chi-square (11, pp. 186-7). The differences in individual gene and antigen frequencies were tested by individual normal deviate tests in which the standard errors are computed from the standard formulas evaluated under the null hypothesis of no difference in the two groups. Throughout the paper, the statistical tests are of the two-sided kind with the significance levels adjusted by correcting for the number of alleles in each segregational series (12 (13, pp. 253-6) was performed comparing each patient as to the presence of HL-A2 with all his sibs. This was not significant. For no allele in either segregational series did either of these statistical tests reach significance when properly adjusted for the number of alleles.
As with the whole ALL group, the subset of 40 patients differ significantly overall from the normals for the first segregational series (P -'0.007) and the gene and antigen frequencies of HL-A2 differ significantly (P -0.01) from the normal groups. These are the only significant differences found between any of the groups of Table II and the 200 normal controls. In all the comparison noted above, the P values are adjusted to take into account the number of alleles being compared within each of the two segregational series. Adjustment to the consideration of both series simultaneously requires multiplication of P by a factor approximately equal to two. Thus the results on the enhanced frequency of HL-A2 in the ALL groups remain highly significant when both series are considered simultaneously. Only one of the patient-mother combinations was haplotypically identical (see Fig. 1 ). All of the other 49 such combinations were not identical. (6) in finding no such decrease. Similarly Sanderson ' did not find any significant difference between his leukemic and control groups for this antigen.
Sanderson found significant decreases in HL-A9 and HL-A10 among his leukemic group. However, if his statistical tests are adjusted for the number of tests being made, their P values rise to about 0.3, so that their results are comparable with those of this paper. The other papers reporting on these antigens do not confirm any marked decrease of these antigens among the leukemic patients.
Turning to the second segregational series, we find that our results for HL-A12 are in contrast to Walford et al., who found this antigen to be more frequent in his leukemic series (5). However, his study was small, and the antiserum used, Merritt, apparently contains other antibodies than anti-12. We note in Table  III that ' reports a significant increase in this antigen among his 48 leukemics, a significance which is sustained by the adjusted statistical analysis. We do not have his detailed data available so we cannot test statistically whether this difference from our results may be due to chance.
Of note, however, is the family illustrated in Fig. 1 . If the A2-A12 haplotype was associated with leukemia, one would expect a person homozygous for it to be very susceptible. Such was not the case in this family, as two unaffected siblings are A2, A12 homozygous. In 11 other families (Nos. 5, 14, 15, 20, 24, 25, 29, 36, 40, 47, 50) at least one unaffected sibling had the A2, A12 haplotype. In only 6 of these 11 families did* the patient have the A2, A12 haplotype. From these data we conclude that this haplotype is not associated with ALL.
Our data and that of others (4, 5, 7, footnote 2) suggest an association between HL-A2 and acute lymphocytic leukemia. If this is so, it is more likely that A2 confers susceptibility to leukemia, than another antigen conferring resistance, since in our series no other single defined antigen is significantly decreased in frequency in the ALL population. To be sure, antigen(s) X (first segregational series) is significantly lower in this population, but X represents a multiplicity of as yet undefined antigens low in frequency and most people would not possess X. In contrast, most people are resistant to leukemia.
The association of an HL-A antigen with leukemia suggests an etiologic relationship. Four possibilities, all speculation, come to mind. These have been previously stated by Snell (17) and Lilly (18) . One, the antigen molecule may serve as a receptor for the leukemia virus. Secondly, the molecule may be immunochemically similar to the virus or to a tumor-specific antigen induced by the virus allowing for persistent infection or tumor growth by the mechanism of cross tolerance. Thirdly, the presence of the HL-A antigen molecule in the cell membrane may be a structural necessity for cell surface changes which lead to malignant behavior. Finally, the gene determining the HL-A antigen may be linked to a gene which controls the host's immune response to a leukemia virus or to a tumor-specific cell surface antigen.
The first three of these hypotheses require only the presence of HL-A2 on the cell membrane and do not require that the subject be homozygous for the gene controlling HL-A2. Our data, which show that 30 of 36 HL-A2 bearing leukemics are heterozygous for the antigen, could fit well with these hypotheses.
The first hypothesis is attractive. HL-A antigens are cell surface molecules and cell surface molecules do act as viral attachment sites. However, this explanation alone is inadequate to explain leukemogenesis as 28% of our population of ALL patients were negative for A2. Presumably, they would not have the receptor unless some closely related but serologically different molecule could substitute for A2. At present, the only serologically cross-reacting, and thus structurally related, specificity for A2 is Lcl7. Those patients in the present study who are negative for A2 were also negative for Lcl7. On the other hand, it is of note that the amino acid composition of soluble HL-A antigen derived from an A2-positive cell line (RPMI 4265) is very similar to that derived from an A2-negative cell line (RAJI) (19) . It may well be that the basic HL-A molecule is constant enough in most of its structure and that the virus is flexible enough to allow for some minor (serologically detectable) differences in receptor molecule specificity.
The second and third hypotheses are also attractive but suffer from the same criticism as the first, i.e., not all leukemics have HL-A2. Since a human leukemia virus has not been isolated, the second hypothesis cannot be tested. A test of the third may be possible by careful quantitative assessment of HL-A2 content on normal and neoplastic lymphocytes, as changes in the amount of the antigen may indicate participation in cell membrane structural realignments that result in malignancy.
The final hypothesis seems unlikely on the surface. Since there was no single HL-A antigen which was significantly decreased in the ALL group, we cannot conclude that our patients lack an immune response gene which confers resistance to leukemia. However, it is possible that the gene controlling HL-A2 is linked to an immune response gene which allows a low (or absent) response to leukemia antigens. In order for the HL-A2 heterozygote to be susceptible to leukemia, this low response gene would have to be at least codominant. Most of the histocompatibility linked immune response genes studied thus far (20) show recessive behavior of genes controlling low or absent response to antigen. Since A2 appears associated with ALL, those races with lower gene frequencies of A2 would be expected to have a lower leukemia incidence. This is true of the negro race which has both low A2 gene frequency and low incidence of leukemia (21, 22 2, Te5O/Th, 7; 1, ?/11, Te5O; 1, ?/11, Te5O 8 1, Te5O/X, X 9, X/LcI7, W14 1, Te5O/9, X X, X/Lc17, W14; X, X/Lc17, W14 9 2, X/3, X 2, X/11, Te5O 2, X/11, Te5O 2, X/11, Te5O; 2, X/2, X 10 1, W14/Th, W1O 10, X/X, 5 1, W14/X, 5
1, W14/X, 5; 1, W14/X, 5; 1, W14/10, X; Th, W1O/X, 5
